135 related articles for article (PubMed ID: 32803999)
21. Therapy-related myeloid neoplasm with bone marrow involvement, myelosarcoma, and a t(8;16)(p11.2;p13.3)-a case report.
Chakraborty S; Adams J; Nassiri M; Vance GH
Cancer Genet; 2014; 207(10-12):511-5. PubMed ID: 25487769
[TBL] [Abstract][Full Text] [Related]
22. Spontaneous remission in patients with acute myeloid leukemia with t(8;21) or cutaneous myeloid sarcoma: two case reports and a review of the literature.
Zeng Q; Yuan Y; Li P; Chen T
Intern Med; 2013; 52(11):1227-33. PubMed ID: 23728561
[TBL] [Abstract][Full Text] [Related]
23. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
[TBL] [Abstract][Full Text] [Related]
24. ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.
Yamato G; Shiba N; Yoshida K; Shiraishi Y; Hara Y; Ohki K; Okubo J; Okuno H; Chiba K; Tanaka H; Kinoshita A; Moritake H; Kiyokawa N; Tomizawa D; Park MJ; Sotomatsu M; Taga T; Adachi S; Tawa A; Horibe K; Arakawa H; Miyano S; Ogawa S; Hayashi Y
Genes Chromosomes Cancer; 2017 May; 56(5):382-393. PubMed ID: 28063196
[TBL] [Abstract][Full Text] [Related]
25. [A new prognostic stratification for patients with acute myeloid leukemia].
Jiang B; Mi YC; Lin D; Cai XJ; Fu MW; Li W; Wang Y; Liu XP; Xue YP; Bian SG; Wang JX
Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):316-20. PubMed ID: 19576124
[TBL] [Abstract][Full Text] [Related]
26. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
Grimwade D; Walker H; Oliver F; Wheatley K; Harrison C; Harrison G; Rees J; Hann I; Stevens R; Burnett A; Goldstone A
Blood; 1998 Oct; 92(7):2322-33. PubMed ID: 9746770
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Parameters of Acute Myeloid Leukaemia at Presentation.
Jahic A; Iljazovic E; Hasic S; Arnautovic AC; Sabitovic D; Mesanovic S; Sahovic H; Simendic V
Med Arch; 2017 Feb; 71(1):20-24. PubMed ID: 28428668
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological characteristics, genetics and prognosis of patients with myeloid sarcoma: a single-center study.
Demir D; Hekimgil M; Karaca E; Ulusoy Y; Özdemir HH; Saydam G; Durmaz B; Akın H; Çetingül N; Tombuloğlu M; Özsan N
J Clin Pathol; 2023 Apr; 76(4):244-251. PubMed ID: 35927017
[TBL] [Abstract][Full Text] [Related]
29. Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
Duan W; Liu X; Zhao X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Shi H; Chang Y; Liu K; Huang X; Qin Y; Jiang H
Ann Hematol; 2021 May; 100(5):1203-1212. PubMed ID: 33474629
[TBL] [Abstract][Full Text] [Related]
30. Nonmyeloablative allogeneic bone marrow transplantation for orbital granulocytic sarcoma associated with t(8;21)(q22;q22) in acute myeloid leukemia.
Hung GY; Chiou TJ; Hsieh YL; Chen PM; Hwang B
Bone Marrow Transplant; 2002 Jan; 29(1):67-70. PubMed ID: 11840147
[TBL] [Abstract][Full Text] [Related]
31. Clinical implications of acute myeloid leukemia presenting as myeloid sarcoma.
Avni B; Rund D; Levin M; Grisariu S; Ben-Yehuda D; Bar-Cohen S; Paltiel O
Hematol Oncol; 2012 Mar; 30(1):34-40. PubMed ID: 21638303
[TBL] [Abstract][Full Text] [Related]
32. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Kern W; Haferlach T; Schoch C; Loffler H; Gassmann W; Heinecke A; Sauerland MC; Berdel W; Buchner T; Hiddemann W
Blood; 2003 Jan; 101(1):64-70. PubMed ID: 12393605
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821.
Chang M; Raimondi SC; Ravindranath Y; Carroll AJ; Camitta B; Gresik MV; Steuber CP; Weinstein H
Leukemia; 2000 Jul; 14(7):1201-7. PubMed ID: 10914543
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological and molecular characteristics of extramedullary acute myeloid leukaemia.
Ullman DI; Dorn D; Jones JA; Fasciano D; Ping Z; Kanakis C; Koenig RG; Salzman D; Peker D
Histopathology; 2019 Aug; 75(2):185-192. PubMed ID: 30916362
[TBL] [Abstract][Full Text] [Related]
35. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
Tsimberidou AM; Kantarjian HM; Estey E; Cortes JE; Verstovsek S; Faderl S; Thomas DA; Garcia-Manero G; Ferrajoli A; Manning JT; Keating MJ; Albitar M; O'Brien S; Giles FJ
Leukemia; 2003 Jun; 17(6):1100-3. PubMed ID: 12764375
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group.
Noort S; Zimmermann M; Reinhardt D; Cuccuini W; Pigazzi M; Smith J; Ries RE; Alonzo TA; Hirsch B; Tomizawa D; Locatelli F; Gruber TA; Raimondi S; Sonneveld E; Cheuk DK; Dworzak M; Stary J; Abrahamsson J; Arad-Cohen N; Czogala M; De Moerloose B; Hasle H; Meshinchi S; van den Heuvel-Eibrink M; Zwaan CM
Blood; 2018 Oct; 132(15):1584-1592. PubMed ID: 30150206
[TBL] [Abstract][Full Text] [Related]
37. Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).
Zhu HH; Jiang H; Jiang Q; Jia JS; Qin YZ; Huang XJ
Leuk Res; 2016 May; 44():40-4. PubMed ID: 26994850
[TBL] [Abstract][Full Text] [Related]
38. Different prognostic effects of core-binding factor positive AML with Korean AML registry data.
Shin HJ; Min WS; Min YH; Cheong JW; Lee JH; Kim IH; Hong DS; Ahn JS; Kim HJ; Lee WS; Jung CW; Jang JH; Park Y; Kim HJ;
Ann Hematol; 2019 May; 98(5):1135-1147. PubMed ID: 30758645
[TBL] [Abstract][Full Text] [Related]
39. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.
Nguyen S; Leblanc T; Fenaux P; Witz F; Blaise D; Pigneux A; Thomas X; Rigal-Huguet F; Lioure B; Auvrignon A; Fière D; Reiffers J; Castaigne S; Leverger G; Harousseau JL; Socié G; Dombret H
Blood; 2002 May; 99(10):3517-23. PubMed ID: 11986202
[TBL] [Abstract][Full Text] [Related]
40. [Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia].
Wu J; Lu AD; Zhang LP; Zuo YX; Jia YP
Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):52-57. PubMed ID: 30704229
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
